{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451-1477", "country": "United States", "phone": "781 895 0600", "website": "https://www.immunogen.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 277, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Joseph Enyedy", "age": 58, "title": "Pres, CEO & Director", "yearBorn": 1964, "fiscalYear": 2021, "totalPay": {"raw": 1244075, "fmt": "1.24M", "longFmt": "1,244,075"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2985041, "fmt": "2.99M", "longFmt": "2,985,041"}}, {"maxAge": 1, "name": "Dr. Anna  Berkenblit M.D., MM.Sc", "age": 52, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2021, "totalPay": {"raw": 647277, "fmt": "647.28k", "longFmt": "647,277"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1305129, "fmt": "1.31M", "longFmt": "1,305,129"}}, {"maxAge": 1, "name": "Ms. Stacy A. Coen", "age": 51, "title": "Sr. VP & Chief Bus. Officer", "yearBorn": 1971, "fiscalYear": 2021, "totalPay": {"raw": 547658, "fmt": "547.66k", "longFmt": "547,658"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 243750, "fmt": "243.75k", "longFmt": "243,750"}}, {"maxAge": 1, "name": "Ms. Renee  Lentini", "age": 44, "title": "Interim CFO, VP of Fin., Chief Accounting Officer & Principal Accounting Officer", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Anabel  Chan", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel S. Char J.D.", "age": 61, "title": "Sr. VP & Chief Legal Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Courtney  O'Konek", "title": "Sr. Director of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Audrey  Bergan", "title": "Sr. VP & Chief HR Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Theresa G. Wingrove", "age": 64, "title": "Sr. VP of Regulatory Affairs & Quality", "yearBorn": 1958, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mary Margaret Huizinga FACP, M.D., M.P.H.", "age": 44, "title": "Sr. VP & Head of Medical Affairs", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 3, "compensationRisk": 7, "shareHolderRightsRisk": 5, "overallRisk": 4, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1640908800}